199735-88-1
199735-88-1
Chemical Structure
CADD522
- CAS No.: 199735-88-1
- Formula:C15H13Cl2NO3
- Molecular Weight:326.17
IUPAC Name: 3-((3,4-dichlorophenyl)carbamoyl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid
InChIKey: YSDNWNOGHQYWPK-UHFFFAOYSA-N
SMILES: ClC1=C(Cl)C=CC(NC(C2C(C3)C=CC3C2C(O)=O)=O)=C1
Biological Activity: CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CADD522 | 98.23% | CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CADD522 (Standard) | CADD522 (Standard) is the analytical standard of CADD522 (HY-107999). This product is intended for research and analytical applications. CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kim MS, et al. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017 Aug 10;8(41):70916-70940. [Content Brief]
- [2]. Kim MS, et al. Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 2020 Oct 27;11(43):3863-3885. [Content Brief]
